Compositions and methods for inhibition of the JAK pathway

US8299087B2 · kind B2 · utility

Assignee

• Rigel Pharmaceuticals, Inc. · US

Inventors

• Hui Li · Santa Clara, US
• Vanessa Taylor · San Francisco, US
• Somasekhar Bhamidipati · Foster City, US
• John Ramphal · Union City, US
• Kin Tso · San Francisco, US
• Arvinder Sran · Fremont, US
• Holger Keim · Irvine, US
• Vadim Markovtsov · San Mateo, US
• David Carroll · San Francisco, US
• Sambaiah Thota · Fremont, US
• Ankush Argade · Foster City, US
• Jeffrey Clough · Redwood City, US
• Rajinder Singh · Belmont, US
• Robin Cooper · St. Augustine, US

Key dates

• Filing date: Oct 11, 2010
• Grant date: Oct 30, 2012
• Expiry date: Nov 10, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.